Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | NMT1 | P30419 | 6/20 | 0.56 |
| ▸ | NMT2 | O60551 | 5/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280087 | 0.98 | SLC6A5 (0.58) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL1673194 | 0.98 | SLC6A5 (0.58) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL30399641 | 0.98 | SLC6A5 (0.58) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL1673186 | 0.98 | SLC6A5 (0.58) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL352420 | 0.98 | SLC6A5 (0.58) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL30905802 | 0.98 | SLC6A5 (0.58) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL23227556 | 0.95 | CTSL (0.56) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL31307690 | 0.95 | SLC6A5 (0.54) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL31307638 | 0.95 | SLC6A5 (0.54) | SLC6A5NMT1NMT2TLR2CTSL | |
| SCHEMBL31307622 | 0.95 | SLC6A5 (0.54) | SLC6A5NMT1NMT2TLR2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161540-A1 | DELIVERY DEVICE | PTT HOLDING APS (DK) | 2025-05-22 | — | — | US | disclosed |
| US-20250026787-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2025-01-23 | — | — | US | disclosed |
| US-12162956-B2 | Peptides and methods for reducing skin pigmentation | GLO PHARMA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118561963-A | Nicotine acetylcholine receptor peptide antagonist conotoxin compositions and related methods | 格罗制药公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4313100-A2 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO Pharma, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117462477-A | delivery device | PTT控股公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230414512-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4218718-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-2427178-B1 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | LABORATORY SKIN CARE INC (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022204305-A2 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-3334413-B1 | A DELIVERY DEVICE | PTT HOLDING APS (DK) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | SLC6A5 4333/4885NMT1 2035/4885NMT2 1166/4885 |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | SLC6A5 4007/4885NMT1 232/4885NMT2 216/4885 |
| US-12162956-B2 | Peptides and methods for reducing skin pigmentation | MC1R, TYR, MC5R | SLC6A5 4333/4885NMT1 2035/4885NMT2 1166/4885 |
| US-20250026787-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | SLC6A5 4333/4885NMT1 2035/4885NMT2 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.